SG Americas Securities LLC Grows Stock Holdings in Inspire Medical Systems, Inc. (NYSE:INSP)

SG Americas Securities LLC increased its stake in Inspire Medical Systems, Inc. (NYSE:INSP) by 114.2% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 6,228 shares of the company’s stock after purchasing an additional 3,321 shares during the quarter. SG Americas Securities LLC’s holdings in Inspire Medical Systems were worth $833,000 at the end of the most recent quarter.

A number of other large investors have also added to or reduced their stakes in the stock. Massmutual Trust Co. FSB ADV increased its position in Inspire Medical Systems by 176,312.5% in the first quarter. Massmutual Trust Co. FSB ADV now owns 14,113 shares of the company’s stock worth $3,031,000 after buying an additional 14,105 shares in the last quarter. Bullseye Asset Management LLC grew its position in shares of Inspire Medical Systems by 119.6% during the fourth quarter. Bullseye Asset Management LLC now owns 27,199 shares of the company’s stock worth $5,534,000 after purchasing an additional 14,812 shares in the last quarter. Private Ocean LLC bought a new stake in Inspire Medical Systems during the 1st quarter valued at approximately $2,738,000. Sumitomo Mitsui Trust Holdings Inc. purchased a new position in Inspire Medical Systems in the 4th quarter worth approximately $1,271,000. Finally, Gilliland Jeter Wealth Management LLC bought a new position in Inspire Medical Systems in the 4th quarter worth approximately $3,369,000. Institutional investors own 94.91% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have recently commented on INSP. Robert W. Baird lowered their target price on shares of Inspire Medical Systems from $220.00 to $200.00 and set an “outperform” rating on the stock in a report on Wednesday, August 7th. KeyCorp cut their price objective on Inspire Medical Systems from $278.00 to $236.00 and set an “overweight” rating for the company in a research report on Wednesday, August 7th. Morgan Stanley decreased their target price on Inspire Medical Systems from $250.00 to $210.00 and set an “overweight” rating on the stock in a research report on Monday, July 15th. Bank of America cut their price target on Inspire Medical Systems from $225.00 to $185.00 and set a “neutral” rating for the company in a report on Monday, June 3rd. Finally, Piper Sandler upped their price objective on Inspire Medical Systems from $250.00 to $255.00 and gave the stock an “overweight” rating in a report on Wednesday, May 8th. Five research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $219.79.

Inspire Medical Systems Trading Down 0.5 %

INSP stock opened at $188.75 on Monday. Inspire Medical Systems, Inc. has a 12 month low of $123.00 and a 12 month high of $257.40. The stock has a market cap of $5.61 billion, a PE ratio of -343.18 and a beta of 1.31. The company has a 50-day moving average price of $152.12 and a 200 day moving average price of $181.57.

Inspire Medical Systems (NYSE:INSP) last announced its earnings results on Tuesday, August 6th. The company reported $0.32 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.14) by $0.46. Inspire Medical Systems had a negative return on equity of 2.82% and a negative net margin of 2.38%. The business had revenue of $195.89 million during the quarter, compared to analyst estimates of $189.08 million. During the same quarter in the previous year, the business earned ($0.41) earnings per share. The company’s revenue for the quarter was up 29.6% compared to the same quarter last year. Sell-side analysts forecast that Inspire Medical Systems, Inc. will post 0.15 EPS for the current year.

Inspire Medical Systems Profile

Inspire Medical Systems, Inc, a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA) in the United States and internationally. The company offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe OSA.